Abstract:Background: Deoxyribonuclease 1 like 3 (DNASE1L3) is a secreted enzyme that has been shown to digest the extracellular chromatin derived from apoptotic bodies, and DNASE1L3 pathogenic variants have been associated with a lupus phenotype. It is unclear whether interferon signaling is sustained in DNASE1L3 deficiency in humans. Objectives: To explore interferon signaling in DNASE1L3 deficient patients. To depict the characteristic features of DNASE1L3 deficiencies in human. Methods: We identified, characterized, and analyzed five new patients carrying biallelic DNASE1L3 variations. Whole or targeted exome and/or Sanger sequencing was performed to detect pathogenic variations in five juvenile systemic erythematosus lupus (jSLE) patients. We measured interferon-stimulated gene (ISG) expression in all patients. We performed a systematic review of all published cases available from its first description in 2011 to March 24th 2022. Results: We identified five new patients carrying biallelic DNASE1L3 pathogenic variations, including three previously unreported mutations. Contrary to canonical type I interferonopathies, we noticed a transient increase of ISGs in blood, which returned to normal with disease remission. Disease in one patient was characterized by lupus nephritis and skin lesions, while four others exhibited hypocomplementemic urticarial vasculitis syndrome. The fourth patient presented also with early-onset inflammatory bowel disease. Reviewing previous reports, we identified 35 additional patients with DNASE1L3 deficiency which was associated with a significant risk of lupus nephritis and a poor outcome together with the presence of anti-neutrophil cytoplasmic antibodies (ANCA). Lung lesions were reported in 6/35 patients. Conclusions: DNASE1L3 deficiencies are associated with a broad phenotype including frequently lupus nephritis and hypocomplementemic urticarial vasculitis with positive ANCA and rarely, alveolar hemorrhages and inflammatory bowel disease. This report shows that interferon production is transient contrary to anomalies of intracellular DNA sensing and signaling observed in Aicardi-Goutières syndrome or STING-associated vasculitis in infancy (SAVI).

Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy

A case of STING‐associated vasculopathy with onset in infancy with novel STING1 variant

Successful Treatment of Stimulator of Interferon Genes–Associated Vasculopathy of Infantile Onset SAVI Syndrome With Anifrolumab

Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype

A rare manifestation of STING-associated vasculopathy with onset in infancy: a case report

Case Report: JAK1/2 Inhibition with Baricitinib in the Treatment of STING-associated Vasculopathy with Onset in Infancy.

Case Report: Novel SAVI-Causing Variants in STING1 Expand the Clinical Disease Spectrum and Suggest a Refined Model of STING Activation

Activation of autoreactive lymphocytes in the lung by radioresistant cells expressing a STING gain-of-function mutation

Serum Syndecan-1 Levels in Patients with Immunoglobulin A Vasculitis in Children

Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China

Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies

Tissue inflammation induced by constitutively active STING is mediated by enhanced TNF signaling

Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltration

Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response

Gain-of-function STING mutations induce T cell death in the SAVI mouse

Sphingosine phosphate lyase insufficiency syndrome as a primary immunodeficiency state

Interstitial Lung Disease and Psoriasis in a Child with Aicardi-Goutières Syndrome

Vasculitis and vasculopathy associated with inborn errors of immunity: an overview

Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus

DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling

Interstitial Lung Disease Associated with Systemic Sclerosis